ISSN 1673-3770 CN 37-1437/R
Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2023, Vol. 37 ›› Issue (3): 125-142.doi: 10.6040/j.issn.1673-3770.0.2022.052
• 综述 • Previous Articles
XU Enpei1, SUN Xianyong2
CLC Number:
| [1] Gonzalez A, Khurshid G. Treatment of retinal pigment epithelial detachment secondary to exudative age-related macular degeneration[J]. Am J Ophthalmol Case Rep, 2018, 9: 18-22. doi:10.1016/j.ajoc.2017.12.004 [2] Yuzawa M, Mori R, Kawamura A. The origins of polypoidal choroidal vasculopathy[J]. Br J Ophthalmol, 2005, 89(5): 602-607. doi:10.1136/bjo.2004.049296 [3] Nakashizuka H, Mitsumata M, Okisaka S, et al. Clinicopathologic findings in polypoidal choroidal vasculopathy[J]. Invest Ophthalmol Vis Sci, 2008, 49(11): 4729-4737. doi:10.1167/iovs.08-2134 [4] Placinta IA, Castro-Seco R, Díaz-Cascajosa J. Pachychoroid neovasculopathy[J]. Arch Soc Esp Oftalmol(Engl Ed), 2020, 95(6): e46. doi:10.1016/j.oftal.2019.12.017 [5] Yannuzzi LA, Ciardella A, Spaide RF, et al. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy[J]. Arch Ophthalmol, 1997, 115(4): 478-485. doi:10.1001/archopht.1997.01100150480005 [6] van Dijk EHC, Mohabati D, Veselinovic S, et al. The spectrum of polypoidal choroidal vasculopathy in Caucasians: clinical characteristics and proposal of a classification[J]. Graefes Arch Clin Exp Ophthalmol, 2021, 259(2): 351-361. doi:10.1007/s00417-020-04844-z [7] Sho K, Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics[J]. Arch Ophthalmol, 2003, 121(10): 1392-1396. doi:10.1001/archopht.121.10.1392 [8] Maller J, George S, Purcell S, et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration[J]. Nat Genet, 2006, 38(9): 1055-1059. doi:10.1038/ng1873 [9] Ferrington DA, Sinha D, Kaarniranta K. Defects in retinal pigment epithelial cell proteolysis and the pathology associated with age-related macular degeneration[J]. Prog Retin Eye Res, 2016, 51: 69-89. doi:10.1016/j.preteyeres.2015.09.002 [10] Kauppinen A, Paterno JJ, Blasiak J, et al. Inflammation and its role in age-related macular degeneration[J]. Cell Mol Life Sci, 2016, 73(9): 1765-1786. doi:10.1007/s00018-016-2147-8 [11] Sepp T, Khan JC, Thurlby DA, et al. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers[J]. Invest Ophthalmol Vis Sci, 2006, 47(2): 536-540. doi:10.1167/iovs.05-1143 [12] Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants[J]. Nat Genet, 2016, 48(2): 134-143. doi:10.1038/ng.3448 [13] Cipriani V, Leung HT, Plagnol V, et al. Genome-wide association study of age-related macular degeneration identifies associated variants in the TNXB-FKBPL-NOTCH4 region of chromosome 6p21.3[J]. Hum Mol Genet, 2012, 21(18): 4138-4150. doi:10.1093/hmg/dds225 [14] Majewski J, Schultz DW, Weleber RG, et al. Age-related macular degeneration: a genome scan in extended families[J]. Am J Hum Genet, 2003, 73(3): 540-550. doi:10.1086/377701 [15] Hughes AE, Orr N, Esfandiary H, et al. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration[J]. Nat Genet, 2006, 38(10): 1173-1177. doi:10.1038/ng1890 [16] Smailhodzic D, Muether PS, Chen J, et al. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration[J]. Ophthalmology, 2012, 119(11): 2304-2311. doi:10.1016/j.ophtha.2012.05.040 [17] Piermarocchi S, Miotto S, Colavito D, et al. Combined effects of genetic and non-genetic risk factors affect response to ranibizumab in exudative age-related macular degeneration[J]. Acta Ophthalmol, 2015, 93(6): e451-e457. doi:10.1111/aos.12587 [18] Parekh N, Voland RP, Moeller SM, et al. Association between dietary fat intake and age-related macular degeneration in the carotenoids in age-related eye disease study(CAREDS): an ancillary study of the Women's Health Initiative[J]. Arch Ophthalmol, 2009, 127(11): 1483-1493. doi:10.1001/archophthalmol.2009.130 [19] Sin HP, Liu DT, Lam DS. Lifestyle modification, nutritional and vitamins supplements for age-related macular degeneration[J]. Acta Ophthalmol, 2013, 91(1): 6-11. doi:10.1111/j.1755-3768.2011.02357.x [20] Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis[J]. BMC Ophthalmol, 2010, 10: 31. doi:10.1186/1471-2415-10-31 [21] Jaisankar D, Swaminathan G, Roy R, et al. Association of obesity and age-related macular degeneration in Indian population[J]. Indian J Ophthalmol, 2018, 66(7): 976-983. doi:10.4103/ijo.IJO_1265_17 [22] Ling CNY, Lim SC, Jonas JB, et al. Obesity and risk of age-related eye diseases: a systematic review of prospective population-based studies[J]. Int J Obes(Lond), 2021, 45(9): 1863-1885. doi:10.1038/s41366-021-00829-y [23] Kaarniranta K, Koskela A, Felszeghy S, et al. Fatty acids and oxidized lipoproteins contribute to autophagy and innate immunity responses upon the degeneration of retinal pigment epithelium and development of age-related macular degeneration[J]. Biochimie, 2019, 159: 49-54. doi:10.1016/j.biochi.2018.07.010 [24] Fernández-Robredo P, Sancho A, Johnen S, et al. Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering[J]. J Ophthalmol, 2014, 2014: 510285. doi:10.1155/2014/510285 [25] Woo SJ, Ahn J, Morrison MA, et al. Analysis of genetic and environmental risk factors and their interactions in Korean patients with age-related macular degeneration[J]. PLoS One, 2015, 10(7): e0132771. doi:10.1371/journal.pone.0132771 [26] Cheung CM, Laude A, Yeo I, et al. Systemic, ocular and genetic risk factors for age-related macular degeneration and polypoidal choroidal vasculopathy in singaporeans[J]. Sci Rep, 2017, 7: 41386. doi:10.1038/srep41386 [27] Ueta T, Obata R, Inoue Y, et al. Background comparison of typical age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients[J]. Ophthalmology, 2009, 116(12): 2400-2406. doi:10.1016/j.ophtha.2009.06.013 [28] Zhang X, Li M, Wen F, et al. Different impact of high-density lipoprotein-related genetic variants on polypoidal choroidal vasculopathy and neovascular age-related macular degeneration in a Chinese Han population[J]. Exp Eye Res, 2013, 108: 16-22. doi:10.1016/j.exer.2012.12.005 [29] Zhang X, Wen F, Zuo CG, et al. Association of genetic variation on chromosome 9p21 with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration[J]. Invest Ophthalmol Vis Sci, 2011, 52(11): 8063-8067. doi:10.1167/iovs.11-7820 [30] Caramoy A, Ristau T, Lechanteur YT, et al. Environmental and genetic risk factors for retinal angiomatous proliferation[J]. Acta Ophthalmol, 2014, 92(8): 745-748. doi:10.1111/aos.12437 [31] Gross NE, Aizman A, Brucker A, et al. Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation[J]. Retina, 2005, 25(6): 713-718. doi:10.1097/00006982-200509000-00005 [32] Ye ZM, Shuai P, Zhai YR, et al. Associations of 6p21.3 region with age-related macular degeneration and polypoidal choroidal vasculopathy[J]. Sci Rep, 2016, 6: 20914. doi:10.1038/srep20914 [33] Han L, Ma Z, Wang C, et al. Morphologic features and viability analysis of human detached retinal pigment epithelium in age-related macular degeneration[J]. Am J Ophthalmol, 2013, 155(3): 474-483.e2. doi:10.1016/j.ajo.2012.09.010 [34] Szatmári-Tóth M, Kristóf E, Veréb Z, et al. Clearance of autophagy-associated dying retinal pigment epithelial cells - a possible source for inflammation in age-related macular degeneration[J]. Cell Death Dis, 2016, 7(9): e2367. doi:10.1038/cddis.2016.133 [35] Gibson NJ, Brown MF. Lipid headgroup and acyl chain composition modulate the MI-MII equilibrium of rhodopsin in recombinant membranes[J]. Biochemistry, 1993, 32(9): 2438-2454. doi:10.1021/bi00060a040 [36] Nowak JZ. Oxidative stress, polyunsaturated fatty acids-derived oxidation products and bisretinoids as potential inducers of CNS diseases: focus on age-related macular degeneration[J]. Pharmacol Rep, 2013, 65(2): 288-304. doi:10.1016/s1734-1140(13)71005-3 [37] Jarrett SG, Boulton ME. Consequences of oxidative stress in age-related macular degeneration[J]. Mol Aspects Med, 2012, 33(4): 399-417. doi:10.1016/j.mam.2012.03.009 [38] Kaemmerer E, Schutt F, Krohne TU, et al. Effects of lipid peroxidation-related protein modifications on RPE lysosomal functions and POS phagocytosis[J]. Invest Ophthalmol Vis Sci, 2007, 48(3): 1342-1347. doi:10.1167/iovs.06-0549 [39] Tan W, Zou J, Yoshida S, et al. The role of inflammation in age-related macular degeneration[J]. Int J Biol Sci, 2020, 16(15): 2989-3001. doi:10.7150/ijbs.49890 [40] Krohne TU, Stratmann NK, Kopitz J, et al. Effects of lipid peroxidation products on lipofuscinogenesis and autophagy in human retinal pigment epithelial cells[J]. Exp Eye Res, 2010, 90(3): 465-471. doi:10.1016/j.exer.2009.12.011 [41] Blasiak J, Piechota M, Pawlowska E, et al. Cellular senescence in age-related macular degeneration: can autophagy and DNA damage response play a role? [J]. Oxid Med Cell Longev, 2017, 2017: 5293258. doi:10.1155/2017/5293258 [42] Kumar MV, Nagineni CN, Chin MS, et al. Innate immunity in the Retina: toll-like receptor(TLR)signaling in human retinal pigment epithelial cells[J]. J Neuroimmunol, 2004, 153(1/2): 7-15. doi:10.1016/j.jneuroim.2004.04.018 [43] Nozaki M, Raisler BJ, Sakurai E, et al. Drusen complement components C3a and C5a promote choroidal neovascularization[J]. PNAS, 2006, 103(7): 2328-2333. doi:10.1073/pnas.0408835103 [44] Zhu Y, Dai B, Li Y, et al. C5a and toll-like receptor 4 crosstalk in retinal pigment epithelial cells[J]. Mol Vis, 2015, 21: 1122-1129. PMID: 26487798. [45] Bert G, Merriam JE, Jana Z, et al. Variation in factor B(BF)and complement component 2(C2)genes is associated with age-related macular degeneration[J]. Nat Genet, 2006, 38(4): 458-462. doi:10.1038/ng1750 [46] Bressler NM, Silva JC, Bressler SB, et al. Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration[J]. Retina, 1994, 14(2): 130-142. doi: 10.1097/00006982-199414020-00006 [47] Pauleikhoff D, Löffert D, Spital G, et al. Pigment epithelial detachment in the elderly[J]. Graefe's Arch Clin Exp Ophthalmol, 2002, 240(7): 533-538. doi:10.1007/s00417-002-0505-8 [48] 邓宝娣, 李嘉, 王庭槐. 脉络膜新生血管相关信号通路研究进展[J]. 国际眼科杂志, 2019, 19(5): 762-765. doi:10.3980/j.issn.1672-5123.2019.5.12 DENG Baodi, LI Jia, WANG Tinghuai. Recent advances in signaling pathways related to choroidal neovascularization[J]. International Eye Science, 2019, 19(5): 762-765. doi:10.3980/j.issn.1672-5123.2019.5.12 [49] Palkar AH, Khetan V. Polypoidal choroidal vasculopathy: an update on current management and review of literature[J]. Taiwan J Ophthalmol, 2019, 9(2): 72-92. doi:10.4103/tjo.tjo_35_18 [50] Kuroiwa S, Tateiwa H, Hisatomi T, et al. Pathological features of surgically excised polypoidal choroidal vasculopathy membranes[J]. Clin Exp Ophthalmol, 2004, 32(3): 297-302. doi:10.1111/j.1442-9071.2004.00827.x [51] Okubo A, Sameshima M, Uemura A, et al. Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study[J]. Br J Ophthalmol, 2002, 86(10): 1093-1098. doi:10.1136/bjo.86.10.1093 [52] Kondo N, Honda S, Ishibashi K, et al. Elastin gene polymorphisms in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy[J]. Invest Ophthalmol Vis Sci, 2008, 49(3): 1101-1105. doi:10.1167/iovs.07-1145 [53] Moussa K, Bloomer MM, Schwartz DM, et al. Polypoidal choroidal vasculopathy: a clinicopathologic study[J]. Retin Cases Brief Rep, 2017, 11(Suppl 1): S128-S131. doi:10.1097/ICB.0000000000000464 [54] Khan S, Engelbert M, Imamura Y, et al. Polypoidal choroidal vasculopathy: simultaneous indocyanine green angiography and eye-tracked spectral domain optical coherence tomography findings[J]. Retina, 2012, 32(6): 1057-1068. doi:10.1097/IAE.0b013e31823beb14 [55] Chen L, Zhang XZ, Li ML, et al. Age-related scattered hypofluorescent spots on late-phase indocyanine green angiography as precursor lesions of polypoidal choroidal vasculopathy[J]. Investig Ophthalmol Vis Sci, 2019, 60(6): 2102-2109. doi:10.1167/iovs.19-26968 [56] Li M, Zhang X, Liao N, et al. Analysis of the serum lipid profile in polypoidal choroidal vasculopathy[J]. Sci Rep, 2016, 6: 38342. doi:10.1038/srep38342 [57] Nakajima M, Yuzawa M, Shimada H, et al. Correlation between indocyanine green angiographic findings and histopathology of polypoidal choroidal vasculopathy[J]. Jpn J Ophthalmol, 2004, 48(3): 249-255. doi:10.1007/s10384-003-0057-4 [58] Terasaki H, Miyake Y, Suzuki T, et al. Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation[J]. Br J Ophthalmol, 2002, 86(3): 321-327. doi:10.1136/bjo.86.3.321 [59] Lafaut BA, Aisenbrey S, Vanden Broecke C, et al. Clinicopathological correlation of deep retinal vascular anomalous complex in age related macular degeneration[J]. Br J Ophthalmol, 2000, 84(11): 1269-1274. doi:10.1136/bjo.84.11.1269 [60] Tsai ASH, Cheung N, Gan ATL, et al. Retinal angiomatous proliferation[J]. Surv Ophthalmol, 2017, 62(4): 462-492. doi:10.1016/j.survophthal.2017.01.008 [61] Baek J, Lee JH, Kim JY, et al. Geographic atrophy and activity of neovascularization in retinal angiomatous proliferation[J]. Invest Ophthalmol Vis Sci, 2016, 57(3): 1500-1505. doi:10.1167/iovs.15-18837 [62] Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von hippel-lindau ubiquitylation complex by O2-regulated prolyl hydroxylation[J]. Science, 2001, 292(5516): 468-472. doi:10.1126/science.1059796 [63] Grimm C, Wenzel A, Groszer M, et al. HIF-1-induced erythropoietin in the hypoxic Retina protects against light-induced retinal degeneration[J]. Nat Med, 2002, 8(7): 718-724. doi:10.1038/nm723 [64] Caprara C, Grimm C. From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease[J]. Prog Retin Eye Res, 2012, 31(1): 89-119. doi:10.1016/j.preteyeres.2011.11.003 [65] Yannuzzi LA, Negrão S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration[J]. Retina, 2001, 21(5): 416-434. doi:10.1097/00006982-200110000-00003 [66] Liaskos M, Asvestas PA, Matsopoulos GK, et al. Detection of retinal pigment epithelium detachment from OCT images using multiscale Gaussian filtering[J]. Technol Health Care, 2019, 27(3): 301-316. doi:10.3233/THC-181501 [67] 张怡, 姚静, 王肖华, 等. 光学相干断层扫描诊断息肉状脉络膜血管病变的敏感性和特异性[J]. 南方医科大学学报, 2017, 37(2): 165-171. doi:10.3969/j.issn.1673-4254.2017.02.04 ZHANG Yi, YAO Jing, WANG Xiaohua, et al. Sensitivity and specificity of optical coherence tomography in diagnosing polypoidal choroidal vasculopathy[J]. Journal of Southern Medical University, 2017, 37(2): 165-171. doi:10.3969/j.issn.1673-4254.2017.02.04 [68] Talks J, Koshy Z, Chatzinikolas K. Use of optical coherence tomography, fluorescein angiography and indocyanine green angiography in a screening clinic for wet age-related macular degeneration[J]. Br J Ophthalmol, 2007, 91(5): 600-601. doi:10.1136/bjo.2006.108043 [69] Krebs I, Glittenberg C, Hagen S, et al. Retinal angiomatous proliferation: morphological changes assessed by Stratus and Cirrus OCT[J]. Ophthalmic Surg Lasers Imaging, 2009, 40(3): 285-289. doi:10.3928/15428877-20090430-10 [70] Ozawa S, Ishikawa K, Ito Y, et al. Differences in macular morphology between polypoidal choroidal vasculopathy and exudative age-related macular degeneration detected by optical coherence tomography[J]. Retina, 2009, 29(6): 793-802. doi:10.1097/IAE.0b013e3181a3b7d9 [71] Srour M, Querques G, Souied EH. Optical coherence tomography angiography of idiopathic polypoidal choroidal vasculopathy[J]. Dev Ophthalmol, 2016, 56: 71-76. doi:10.1159/000442781 [72] Soman M, Sheth JU, Indurkar A, et al. De-novo multilayering in fibrovascular pigment epithelial detachment[J]. Sci Rep, 2021, 11(1): 17209. doi:10.1038/s41598-021-96746-1 [73] Degenhardt V, Khoramnia R, Storr J, et al. Intraoperative OCT in retinal detachment with macular involvement[J]. Ophthalmologe, 2021, 118(8): 810-817. doi:10.1007/s00347-020-01238-8 [74] Imamura Y, Engelbert M, Iida T, et al. Polypoidal choroidal vasculopathy: a review[J]. Surv Ophthalmol, 2010, 55(6): 501-515. doi:10.1016/j.survophthal.2010.03.004 [75] Do DV, Gower EW, Cassard SD, et al. Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study[J]. Ophthalmology, 2012, 119(4): 771-778. doi:10.1016/j.ophtha.2011.10.019 [76] Park EA, Tsikata E, Lee JJ, et al. Artifact rates for 2D retinal nerve fiber layer thickness versus 3D neuroretinal rim thickness using spectral-domain optical coherence tomography[J]. Transl Vis Sci Technol, 2020, 9(10): 10. doi:10.1167/tvst.9.10.10 [77] Lee JE, Kim HW, Lee SJ, et al. Changes of choroidal neovascularization in indocyanine green angiography after intravitreal ranibizumab injection[J]. Retina, 2015, 35(5): 999-1006. doi:10.1097/IAE.0000000000000432 [78] Rush RB, Rush SW. Evaluation of idiopathic choroidal neovascularization with indocyanine green angiography in patients undergoing bevacizumab therapy[J]. J Ophthalmol, 2015, 2015: 642624. doi:10.1155/2015/642624 [79] Puliafito CA. OCT angiography: the next era of OCT technology emerges[J]. Ophthalmic Surg Lasers Imaging Retina, 2014, 45(5): 360. doi:10.3928/23258160-20140925-01 [80] Coscas G, Lupidi M, Coscas F. Heidelberg spectralis optical coherence tomography angiography: technical aspects[J]. Dev Ophthalmol, 2016, 56: 1-5. doi:10.1159/000442768 [81] Jia Y, Tan O, Tokayer J, et al. Split-spectrum amplitude-decorrelation angiography with optical coherence tomography[J]. Opt Express, 2012, 20(4): 4710-4725. doi:10.1364/OE.20.004710 [82] 毛剑波, 林晶晶, 沈丽君, 等. 光相干断层扫描血管成像对息肉样脉络膜血管病变异常分支血管网及息肉样病灶的检出率分析[J]. 中华眼底病杂志, 2018, 34(1): 65-66. doi:10.3760/cma.j.issn.1005-1015.2018.01.016 [83] Perrott-Reynolds R, Cann R, Cronbach N, et al. The diagnostic accuracy of OCT angiography in naive and treated neovascular age-related macular degeneration: a review[J]. Eye(Lond), 2019, 33(2): 274-282. doi:10.1038/s41433-018-0229-6 [84] Spaide RF, Klancnik JM Jr, Cooney MJ. Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography[J]. JAMA Ophthalmol, 2015, 133(1): 45-50. doi:10.1001/jamaophthalmol.2014.3616 [85] Miere A, Querques G, Semoun O, et al. Optical coherence tomography angiography changes in early type 3 neovascularization after anti-vascular endothelial growth factor treatment[J]. Retina, 2017, 37(10): 1873-1879. doi:10.1097/iae.0000000000001447 [86] Kim JY, Kwon OW, Oh HS, et al. Optical coherence tomography angiography in patients with polypoidal choroidal vasculopathy[J]. Graefes Arch Clin Exp Ophthalmol, 2016, 254(8): 1505-1510. doi:10.1007/s00417-015-3228-3 [87] Takayama K, Ito Y, Kaneko H, et al. Comparison of indocyanine green angiography and optical coherence tomographic angiography in polypoidal choroidal vasculopathy[J]. Eye(Lond), 2017, 31(1): 45-52. doi:10.1038/eye.2016.232 [88] Gunnemann F, Rothaus K, Farecki ML, et al. OCT-angiografie Bei exsudativer AMD mit vaskularisierter pigmentepithelabhebung[J]. Klin Monatsbl Augenheilkd, 2017, 234(9): 1132-1138. doi:10.1055/s-0043-118345 [89] Sarraf D, London NJS, Khurana RN, et al. Ranibizumab treatment for pigment epithelial detachment secondary to neovascular age-related macular degeneration: post hoc analysis of the HARBOR study[J]. Ophthalmology, 2016, 123(10): 2213-2224. doi:10.1016/j.ophtha.2016.07.007 [90] Waldstein SM, Simader C, Staurenghi G, et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials[J]. Ophthalmology, 2016, 123(7): 1521-1529. doi:10.1016/j.ophtha.2016.03.037 [91] Schmidt-Erfurth U, Waldstein SM, Deak GG, et al. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration[J]. Ophthalmology, 2015, 122(4): 822-832. doi:10.1016/j.ophtha.2014.11.017 [92] Tyagi P, Juma Z, Hor YK, et al. Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept[J]. BMC Ophthalmol, 2018, 18(1): 148. doi:10.1186/s12886-018-0824-0 [93] Ersoy L, Ristau T, Kirchhof B, et al. Response to anti-VEGF therapy in patients with subretinal fluid and pigment epithelial detachment on spectral-domain optical coherence tomography[J]. Graefes Arch Clin Exp Ophthalmol, 2014, 252(6): 889-897. doi:10.1007/s00417-013-2519-9 [94] Freeman WR, Kozak I, Yuson RMS, et al. Prognosti implications of pigment epithelial detachment in bevacizumab(avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization[J]. Retina, 2011, 31(9): 1812-1818. doi:10.1097/IAE.0b013e31821987a4 [95] Balaskas K, Karampelas M, Horani M, et al. Quantitative analysis of pigment epithelial detachment response to different anti-vascular endothelial growth factor agents in wet age-related macular degeneration[J]. Retina, 2017, 37(7): 1297-1304. doi:10.1097/IAE.0000000000001342 [96] Bolz M, Michels S, Geitzenauer W, et al. Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment[J]. Br J Ophthalmol, 2007, 91(6): 785-789. doi:10.1136/bjo.2006.102467 [97] Blair MP, Gupta M, Blair NP, et al. Association between retinal thickness and retinal pigment epithelium elevation in age-related macular degeneration[J]. Ophthalmic Surg Lasers Imaging, 2010, 41(2): 175-181. doi:10.3928/15428877-20100303-04 [98] Leitritz M, Gelisken F, Inhoffen W, et al. Can the risk of retinal pigment epithelium tears after bevacizumab treatment be predicted? An optical coherence tomography study[J]. Eye(Lond), 2008, 22(12): 1504-1507. doi:10.1038/eye.2008.145 [99] Chan CK, Abraham P, Meyer CH, et al. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections[J]. Retina, 2010, 30(2): 203-211. doi:10.1097/IAE.0b013e3181babda5 [100] Hoskin A, Bird AC, Sehmi K. Tears of detached retinal pigment epithelium[J]. Br J Ophthalmol, 1981, 65(6): 417-422. doi:10.1136/bjo.65.6.417 [101] Haller Yeo J, Marcus S, Murphy RP. Retinal pigment epithelial tears: patterns and prognosis[J]. Ophthalmology, 1988, 95(1): 8-13. doi:10.1016/S0161-6420(88)33233-1 [102] Sastre-Ibáñez M, Martínez-Rubio C, Molina-Pallete R, et al. Retinal pigment epithelial tears[J]. J Français D'ophtalmologie, 2019, 42(1): 63-72. doi:10.1016/j.jfo.2018.04.017 [103] Sarraf D, Reddy S, Chiang A, et al. A new grading system for retinal pigment epithelial tears[J]. Retina, 2010, 30(7): 1039-1045. doi:10.1097/IAE.0b013e3181cdf366 [104] Lesniak SP, Fine HF, Prenner JL, et al. Long-term follow-up of spontaneous retinal pigment epithelium tears in age-related macular degeneration treated with anti-VEGF therapy[J]. Eur J Ophthalmol, 2011, 21(1): 73-76. doi:10.5301/ejo.2010.2285 [105] Cho HJ, Kim HS, Yoo SG, et al. Retinal pigment epithelial tear after intravitreal ranibizumab treatment for neovascular age-related macular degeneration[J]. Retina, 2016, 36(10): 1851-1859. doi:10.1097/IAE.0000000000001009 [106] Yu JJ, Agrón E, Clemons TE, et al. Natural history of drusenoid pigment epithelial detachment associated with age-related macular degeneration: age-related eye disease study 2 report no. 17[J]. Ophthalmology, 2019, 126(2): 261-273. doi:10.1016/j.ophtha.2018.08.017 [107] Cukras C, Agrón E, Klein ML, et al. Natural history of drusenoid pigment epithelial detachment in age-related macular degeneration: age-Related Eye Disease Study Report No. 28[J]. Ophthalmology, 2010, 117(3): 489-499. doi:10.1016/j.ophtha.2009.12.002 [108] Kim MS, Ryoo NK, Park KH. Laser and anti-vascular endothelial growth factor treatment for drusenoid pigment epithelial detachment in age-related macular degeneration[J]. Sci Rep, 2020, 10(1): 14370. doi:10.1038/s41598-020-71401-3 [109] The morrfields macular study group. Retinal pigment epithelial detachments in the elderly: a controlled trial of Argon laser photocoagulation[J]. Br J Ophthalmol, 1982, 66(1): 1-16. doi:10.1136/bjo.66.1.1 [110] Barondes MJ, Pagliarini S, Chisholm IH, et al. Controlled trial of laser photocoagulation of pigment epithelial detachments in the elderly: 4 year review[J]. Br J Ophthalmol, 1992, 76(1): 5-7. doi:10.1136/bjo.76.1.5 [111] 陈青山, 陈璐, 赵霞, 等. 微脉冲激光阈值下治疗黄斑软性玻璃膜疣和玻璃膜疣性DPED的形态学改变[J]. 国际眼科杂志, 2020, 20(6): 934-939. doi:10.3980/j.issn.1672-5123.2020.6.02 CHEN Qingshan, CHEN Lu, ZHAO Xia, et al. Morphological changes of macular soft drusen and drusenoid DPED after subthreshold micropulse laser treatment[J]. International Eye Science, 2020, 20(6): 934-939. doi:10.3980/j.issn.1672-5123.2020.6.02 [112] Huang Z, Deng KY, Deng YM, et al. Long-term outcomes of drusenoid pigment epithelium detachment in intermediate AMD treated with 577 nm subthreshold micropulse laser: a preliminary clinical study[J]. Int J Ophthalmol, 2022, 15(3): 474-482. doi:10.18240/ijo.2022.03.16 [113] Sheth J, Anantharaman G, Chandra S, et al. Management of recalcitrant polypoidal choroidal vasculopathy by feeder vessel laser photocoagulation[J]. Am J Ophthalmol Case Rep, 2018, 9: 112-115. doi:10.1016/j.ajoc.2018.01.031 [114] Monés J, Badal J, Biarnés M. Feeder vessel laser photocoagulation for idiopathic, subfoveal polypoidal choroidal vasculopathy not responding to either anti-vascular endothelial growth factor therapy or photodynamic therapy[J]. RETINAL Cases Brief Rep, 2016, 10(1): 100-103. doi:10.1097/icb.0000000000000174 [115] Szentmáry N, Goebels S, Bischoff M, et al. Photodynamische therapie Bei infektiöser keratitis[J]. Der Ophthalmol, 2012, 109(2): 165-170. doi:10.1007/s00347-011-2511-x [116] O'Day RF, Pejnovic TM, Isaacs T, et al. Australian and new Zealand study of photodynamic therapy in choroidal amelanotic melanoma[J]. Retina, 2020, 40(5): 972-976. doi:10.1097/IAE.0000000000002520 [117] Yoshida I, Taniguchi H, Sakamoto M, et al. Association between the degree of inclusion of components identified on fluorescein or indocyanine green angiography in target spots and relapse of exudate in eyes with polypoidal choroidal vasculopathy and typical age-related macular degeneration after photodynamic therapy[J]. Clin Ophthalmol, 2021, 15: 2063-2075. doi:10.2147/OPTH.S305238 [118] Axer-Siegel R, Ehrlich R, Rosenblatt I, et al. Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration[J]. Arch Ophthalmol, 2004, 122(4): 453-459. doi:10.1001/archopht.122.4.453 [119] Michels S, Hansmann F, Geitzenauer W, et al. Influence of treatment parameters on selectivity of verteporfin therapy[J]. Invest Ophthalmol Vis Sci, 2006, 47(1): 371-376. doi:10.1167/iovs.05-0354 [120] Saito M, Iida T, Nagayama D. Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment[J]. Br J Ophthalmol, 2008, 92(12): 1642-1647. doi:10.1136/bjo.2007.137075 [121] Ladas ID, Kotsolis AI, Rouvas AA, et al. Efficacy of photodynamic therapy in the management of occult choroidal neovascularization associated with serous pigment epithelium detachment[J]. Ophthalmologica, 2007, 221(5): 313-319. doi:10.1159/000104761 [122] Boscia F, Furino C, Sborgia L, et al. Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment[J]. Am J Ophthalmol, 2004, 138(6): 1077-1079. doi:10.1016/j.ajo.2004.06.072 [123] Boscia F, Parodi MB, Furino C, et al. Photodynamic therapy with verteporfin for retinal angiomatous proliferation[J]. Graefes Arch Clin Exp Ophthalmol, 2006, 244(10): 1224-1232. doi:10.1007/s00417-005-0205-2. [124] Teper SJ, Nowinska A, Pilat J, et al. Photodynamic therapy in VEGF inhibition non-responders-Pharmacogenetic study in age-related macular degeneration assessed with swept-source optical coherence tomography[J]. Photodiagnosis Photodyn Ther, 2016, 13: 108-113. doi:10.1016/j.pdpdt.2016.01.006 [125] Tsuchihashi T, Mori K, Ueyama K, et al. Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration[J]. Clin Ophthalmol, 2013, 7: 615-620. doi:10.2147/OPTH.S43566 [126] Cook H L, Patel P J, Tufail A. Age-related macular degeneration: diagnosis and management[J]. Br Med Bull, 2008(1):127-149. [127] Ahmad S, Bearelly S, Stinnett SS, et al. Photodynamic therapy for predominantly hemorrhagic lesions in neovascular age-related macular degeneration[J]. Am J Ophthalmol, 2008, 145(6): 1052-1057. doi:10.1016/j.ajo.2008.02.008 [128] Cheung CMG, Bhargava M, Xiang L, et al. Six-month visual prognosis in eyes with submacular hemorrhage secondary to age-related macular degeneration or polypoidal choroidal vasculopathy[J]. Graefes Arch Clin Exp Ophthalmol, 2013, 251(1): 19-25. doi:10.1007/s00417-012-2029-1 [129] Koizumi H, Kano M, Yamamoto A, et al. Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results[J]. Ophthalmology, 2016, 123(3): 617-624. doi:10.1016/j.ophtha.2015.10.039 [130] 马臻. 年龄相关性黄斑变性的药物治疗[J]. 中国药业, 2012, 21(18): 97-98. doi:10.3969/j.issn.1006-4931.2012.18.064 [131] Freund KB, Mrejen S, Gallego-Pinazo R. An update on the pharmacotherapy of neovascular age-related macular degeneration[J]. Expert Opin Pharmacother, 2013, 14(8): 1017-1028. doi:10.1517/14656566.2013.787410 [132] 刘新书, 王敏, 赵潺, 等. 结膜下注射曲安奈德治疗葡萄膜炎继发黄斑水肿的临床观察[J]. 中华眼科杂志, 2015, 51(10): 734-738. doi:10.3760/cma.j.issn.0412-4081.2015.10.006 [133] Motarjemizadeh Q, Aidenloo NS, Abbaszadeh M, et al. Intravitreal bevacizumab with or without triamcinolone for wet age-related macular degeneration: twelve-month results of a prospective, randomized investigation[J]. Middle East Afr J Ophthalmol, 2018, 25(1): 1-7. doi:10.4103/meajo.MEAJO_292_16 [134] Baumal CR, Bodaghi B, Singer M, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment[J]. Ophthalmol Retina, 2021, 5(6): 519-527. doi:10.1016/j.oret.2020.09.020 [135] Kataoka K, Horiguchi E, Kawano K, et al. Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy[J]. Jpn J Ophthalmol, 2021, 65(2): 199-207. doi:10.1007/s10384-021-00818-8 [136] Tong JP, Chan WM, Liu DTL, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization[J]. Am J Ophthalmol, 2006, 141(3): 456-462. doi:10.1016/j.ajo.2005.10.012 [137] Hu J, Leng X, Hu YJ, et al. The features of inflammation factors concentrations in aqueous humor of polypoidal choroidal vasculopathy[J]. PLoS One, 2016, 11(1): e0147346. doi:10.1371/journal.pone.0147346 [138] Amoaku WM, Chakravarthy U, Gale R, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye(Lond). 2015, 29(10):1397-1398. doi:10.1038/eye.2015.159. [139] Tong Y, Zhao KK, Feng D, et al. Comparison of the efficacy of anti-VEGF monotherapy versus PDT and intravitreal anti-VEGF combination treatment in AMD: a Meta-analysis and systematic review[J]. Int J Ophthalmol, 2016, 9(7): 1028-1037. doi:10.18240/ijo.2016.07.16 [140] Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor(VEGF)and related ligands by VEGF Trap, ranibizumab and bevacizumab[J]. Angiogenesis, 2012, 15(2): 171-185. doi:10.1007/s10456-011-9249-6 [141] Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept(VEGF trap-eye)in wet age-related macular degeneration[J]. Ophthalmology, 2012, 119(12): 2537-2548. doi:10.1016/j.ophtha.2012.09.006 [142] Zhang M, Zhang JJ, Yan M, et al. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for e |
| [1] | WANG Luping, KOU Fangning, WANG Hao, ZHANG Canwei, WANG Yanling, YOU Ran, WU Weizhen. Effects of subretinal hyperreflective material on the visual prognosis of anti-VEGF therapy in patients with neovascular macular degeneration [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(6): 101-105. |
| [2] | LI ManOverview,FENG Xue, WANG YanlingGuidance. Association between ocular ischemic syndrome and ischemic stroke [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(5): 88-92. |
| [3] | FAN Huijuan，,ZHANG Haili. Advancements of HIF-1α and VEGF in middle ear cholesteatoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(5): 93-97. |
| [4] | ObjectiveTo discuss the causes and appropriate treatment for iris neovascularization following the analysis of cases( eyes). MethodsIt was a retrospective case series study involving patients( eyes)with iris neovascularization diagnosed between September and July . All the patients underwent ophthalmic examination, and all the examination findings and treatments were recorded. The causes, correlative factors, and treatment outcomes of iris neovascularization were analyzed. ResultsOf the patients, ( eyes, .%)had retinal ischemic signs, including vitreous hemorrhage and retinal vascularization on fundus fluorescein angiography, ( eyes, .%)did not have retinal ischemic signs. After months of treatment, retinal vascularization resolved in all the cases, and iris neovascularization resolved completely in patients( eyes, .%), iris neovascularization was still found in patients( eyes, .%). ConclusionsAnterior segment ischemia may also lead to iris vascularization, although retinal ischemia was the main cause. Additionally, iris neovascularization may not always resolve with treatment for retinal ischemia. Finally, anti-VEGF drug injection was an effective treatment for iris neovascularization.. Case analysis of 25 cases of iris neovascularizationLI Xuan1,2, HUANG Yingxiang2 1. Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China; 2. Department of Fundus Disease and Eye Trauma, Eye Hospital China Academy of Chinese Medicine Sciences, Beijing 100040, ChinaAbstract: [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 41-47. |
| [5] | LI Hao, LI Yanzhong, WANG Yan. Hypoxia inducible factor-1 alpha and vascular endothelial growth factor expression in the soft palate of [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2018, 32(2): 43-47. |
| [6] | WANG Cui, YAN Xin, ZHAO Bojun. Combination of intravitreal ranibizumab with photodynamic therapy in the treatment of wet age-related macular degeneration. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(4): 94-97. |
| [7] | . Effects of PGMS on the expression of vascular endothelial growth factor in the rat of diabetic retinopathy. [J]. J Otolaryngol Ophthalmol Shandong Univ, 2017, 31(2): 90-95. |
| [8] | LI Yingying, ZHOU Han, ZHANG Weiqiang, DONG Weida. Effects of silencing hypoxia inducible factor-1α on the expression of cytokines in cultured human nasal epithelial cells [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(5): 38-42. |
| [9] | LI Junying. Effects of rosuvastatin combined with fenofibrate therapy on vascular endothelial function retinopathy diabetic retinopathy patients [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(5): 72-75. |
| [10] | DU Xiangge, ZHANG Yingchun, YAN Xin, WANG Cui, ZHAO Bojun. In vitro study of the effect of Casein Kinase2 siRNA on anginogesis [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(3): 76-80. |
| [11] | ZHANG Ying-chun, DU Xiang-ge, YAN Xin, WANG Cui, ZHAO Bo-jun. Effect of nicotine on human RPE cells and HUVECs [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(2): 74-80. |
| [12] | MIAO Bei-ping1， ZHANG Rui-shi2， GUO Zhi-hong3， SUN Huan-ji1， MENG Qing-guo1， WANG Xiao-bin1. Correlation analysis of VEGF expression and the content of dendritic cells in nasopharyngeal carcinoma and its clinical significance [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(4): 62-65. |
| [13] | XIE Li, WEI wei. Treatment progress of diabetic macular edema [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(2): 81-85. |
| [14] | LI Li-hua, REN Ji-hao, YIN Tuan-fang, LIU Wei. Role of expressions of STAT3,VEGF and micro-vessel density in recurrence and invasiveness of juvenile [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2011, 25(6): 11-. |
| [15] |
HAN Xuguang1，2， WU Xinyi1, QU Fei3, SUN Yan2, WANG Xu2, XU Xianghui2 . Corneal neovascularization induced by suture and alkali burn in rabbits: an experimental study [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2009, 23(2): 79-82 . |
|
||